Abstract |
Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alternative treatment options. Carbapenem-resistant gram-negative bacteria of clinical relevance include the Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and more recently, Stenotrophomonas maltophilia. Colistin and tigecycline have been used as first-line agents for the treatment of infections caused by these pathogens; however, there are uncertainties regarding their efficacy even when used in combination with other agents. More recently, several new agents with activity against certain carbapenem-resistant pathogens have been approved for clinical use or are reaching late-stage clinical development. They include ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin- relebactam, plazomicin, eravacycline, and cefiderocol. In addition, fosfomycin has been redeveloped in a new intravenous formulation. Data regarding the clinical efficacy of these new agents specific to infections caused by carbapenem-resistant pathogens are slowly emerging and appear to generally favor newer agents over previous best available therapy. As more treatment options become widely available for carbapenem-resistant gram-negative infections, the role of antimicrobial stewardship will become crucial in ensuring appropriate and rationale use of these new agents.
|
Authors | Yohei Doi |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 69
Issue Suppl 7
Pg. S565-S575
(11 13 2019)
ISSN: 1537-6591 [Electronic] United States |
PMID | 31724043
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. |
Chemical References |
- Anti-Bacterial Agents
- Carbapenems
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Antimicrobial Stewardship
- Carbapenems
(therapeutic use)
- Clinical Trials as Topic
- Drug Resistance, Bacterial
- Forecasting
- Gram-Negative Bacterial Infections
(drug therapy)
- Humans
- Public Health
|